

## CORRESPONDENCE

Anesthesiology  
1999; 91:583  
© 1999 American Society of Anesthesiologists, Inc.  
Lippincott Williams & Wilkins, Inc.

*In Reply:*—The communication to which Dr. Baum refers was not a response to a letter to the editor; instead, it was a *de novo* submission. Dr. Baum also seems confused about the purpose and nature of the Outcomes Research™ Group.

The group was founded in 1990 and now includes 65 members in 10 countries. Our primary interest is large outcome studies; however, we continue to conduct smaller studies. Fewer than half are thermoregulatory, and a fair number are unrelated to anesthesia. We have more than 60 studies in progress, and the group typically publishes more than 20 full articles each year. Most of our funding is derived from peer-reviewed sources, including the National Institutes of Health. However, we are neither a corporation nor a foundation; consequently, all funds are administered by host universities.

Additional information about the group, including a list of members, is available from our web site: [outcomes-research.org](http://outcomes-research.org). This site includes a searchable bibliography of more than 2,500 references related to thermoregulation and other group interests. The entire database can be downloaded in EndNote® format. The web site similarly includes various slide presentations; these PowerPoint® files also can be downloaded for teaching purposes.

Dr. Baum wonders how we can trademark a relatively common term, and what the implication might be. There is no particular difficulty obtaining trademark protection for common terms. Consider, for example, "Palm" of the Palm III organizer. We registered "Outcomes Research" rather than "Outcomes Research Group" for the same reason that the Apple Computer, Inc. registered the term "Apple" rather

than "Apple Computer Company": So we can refer to the group using the shorter and more convenient term. A trademark on Outcomes Research does not preclude casual or descriptive use of the words *outcomes research*. However, it would be inappropriate to use the proper noun Outcomes Research to solicit grants or corporate contracts, especially if doing so engendered any confusion with our group.

We appreciate Dr. Baum's interest in supporting our efforts. Checks can be made payable to the Regents of the University of California and mailed to my attention. Small unmarked bills will also be accepted.

**Daniel I. Sessler, M.D.**

Professor  
Department of Anesthesia  
University of California, San Francisco  
Professor  
Ludwig Boltzmann Institute for Clinical Anesthesia and Intensive Care  
Director  
Outcomes Research™  
Professor and Vice-Chair  
Department of Anesthesia and General Intensive Care  
University of Vienna  
Vienna, Austria  
[ssesslerd@anesthesia.ucsf.edu](mailto:ssesslerd@anesthesia.ucsf.edu)

(Accepted for publication March 23, 1999.)

Anesthesiology  
1999; 91:583-4  
© 1999 American Society of Anesthesiologists, Inc.  
Lippincott Williams & Wilkins, Inc.

## A Reliable Diagnosis of Porphyrria Should Precede any Conclusion Concerning the Safety of a Drug in Porphyrria

*To the Editor:*—Asirvatham *et al.*<sup>1</sup> reported a case of "prolonged loss of consciousness and elevated porphyrins following propofol administration." In view of this, the authors conclude that it might be the first report to doubt whether propofol, an agent considered to be safe in porphyric patients, is indeed safe. However, we doubt the diagnosis of porphyria in this case and, therefore, doubt the conclusion.

To the best of our knowledge, increases in urinary aminolevulinic acid, porphobilinogen, and coproporphyrin III are not necessarily compatible with the diagnosis of coproporphyrria, a diagnosis suggested by the authors. These biochemical findings may be compatible with any type of neurogenic porphyria (coproporphyrria, acute

intermittent, variegate) as a primary cause and also may reflect secondary changes due to other clinical states (e.g., liver injury, effect of drugs, lead poisoning).<sup>2,3</sup> Various biochemical tests, related to porphyrin biosynthetic pathway, conducted in the urine, feces, and blood may indicate which of the aforementioned causes leads to the abnormalities reported in the urine.<sup>4</sup> According to the case report, none of these tests was performed. The diagnosis of coproporphyrria, for example, should be based on disturbed fecal porphyrin profile with elevated coproporphyrin that predominates and a reversed ratio of coproporphyrin III/I (from < 1 in normal patients to up to 30 in coproporphyrria patients).<sup>5,6</sup> To complete the